Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain
Daniel Kwakye Nomah,
Juliana Reyes-Urueña,
Lucía Alonso,
Yesika Díaz,
Sergio Moreno-Fornés,
Jordi Aceiton,
Andreu Bruguera,
Raquel Martín-Iguacel,
Arkaitz Imaz,
Maria del Mar Gutierrez,
Ramón W. Román,
Paula Suanzes,
Juan Ambrosioni,
Jordi Casabona,
Jose M. Miro,
Josep M. Llibre,
the PISCIS Study Group
Affiliations
Daniel Kwakye Nomah
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Juliana Reyes-Urueña
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Lucía Alonso
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Yesika Díaz
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Sergio Moreno-Fornés
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Jordi Aceiton
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Andreu Bruguera
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Raquel Martín-Iguacel
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Arkaitz Imaz
Department of Infectious Diseases, Hospital Universitari de Bellvitge-(IDIBELL), 08907 L’Hospitalet de Llobregat, Spain
Maria del Mar Gutierrez
Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Ramón W. Román
Agència de Qualitat i Avaluació Sanitàries de Catalunya, 08005 Barcelona, Spain
Paula Suanzes
Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), 08035 Barcelona, Spain
Juan Ambrosioni
Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Jordi Casabona
Center for Epidemiological Studies of Sexually Transmitted Diseases and HIV/AIDS in Catalonia (CEEISCAT), Department of Health, Government of Catalunya, 08916 Badalona, Spain
Jose M. Miro
Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
Josep M. Llibre
Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
People with HIV (PWH) may be more susceptible to SARS-CoV-2 infection and worse clinical outcomes. We investigated the disparity in SARS-CoV-2 vaccination coverage between PWH and those without HIV (PWoH) in Catalonia, Spain, assessing primary and monovalent booster vaccination coverage from December 2021 to July 2022. The vaccines administered were BNT162, ChAdOx1-S, mRNA-127, and Ad26.COV2.S. Using a 1:10 ratio of PWH to PWoH based on sex, age, and socioeconomic deprivation, the analysis included 201,630 individuals (183,300 PWoH and 18,330 PWH). Despite a higher prevalence of comorbidities, PWH exhibited lower rates of complete primary vaccination (78.2% vs. 81.8%, p p p p < 0.001). In multivariable logistic regression analysis of the overall population, a prior SARS-CoV-2 diagnosis, HIV status, migrants, and mild-to-severe socioeconomic deprivation were associated with lower primary vaccination coverage, reflecting barriers to healthcare and vaccine access. However, booster vaccination was higher among PWH. Targeted interventions are needed to improve vaccine coverage and address hesitancy in vulnerable populations.